Entero Healthcare Solutions Limited shareholders approved all seven resolutions tabled at its 8th Annual General Meeting (AGM) held on August 19, 2026. The meeting, conducted via video conferencing and other audio-visual means (VC/OAVM), covered ordinary business such as the adoption of audited standalone and consolidated financial statements for FY26, alongside special business regarding director reappointments and management remuneration.

The promoter and promoter group demonstrated near-total engagement, casting votes on 22,807,166 shares out of 22,807,609 held, representing a 99.9981% participation rate. Public institutional shareholders voted on 5,419,725 shares (60.56% of holdings), while public non-institutional shareholders voted on 5,060,043 shares (43.00% of holdings). In total, 33,286,934 votes were polled out of 43,523,072 outstanding shares.

Ordinary Business Outcomes

Shareholders unanimously approved the adoption of the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. Both resolutions received 99.9996% of votes in favor, with only 127 votes cast against each.

Mr. Arun Sadhanandham, Non-Executive Non-Independent Director, was reappointed by rotation. His reappointment resolution secured 99.90% of votes in favor, with 33,117 votes against, primarily from the public institutional category.

Special Business and Remuneration

The special business agenda focused on governance and executive compensation. Shareholders approved the remuneration for Mr. Prabhat Agrawal, Managing Director & CEO, for his remaining tenure with 93.58% of votes in favor. Similarly, the remuneration for Mr. Prem Sethi, Whole Time Director & COO, was approved with 93.95% support.

Two independent directors were reappointed for their second terms: Mr. Sujesh Vasudevan and Ms. Sandhya Gadkari Sharma. Both resolutions received over 94% approval from the total votes polled. Notably, while the promoter group voted unanimously in favor of all special resolutions, public institutional shareholders cast approximately 34-35% of their votes against the remuneration and reappointment proposals.

Voting Participation Breakdown

What the Numbers Show

The voting data reveals a distinct divergence between promoter and institutional shareholder sentiment on governance matters. While the promoter group provided unanimous backing for all resolutions, including executive pay, public institutional investors opposed the remuneration packages for the MD/CEO and WTD/COO with roughly one-third of their votes. This split highlights differing views on executive compensation structures within the shareholder base, despite the resolutions passing comfortably due to promoter dominance.

Entero Healthcare Solutions Limited delivered robust top-line and bottom-line growth in Q1FY27, with consolidated revenue rising 38.2% year-on-year to ₹1,940 crore. The company achieved an EBITDA margin of 5% in the quarter, matching its full-year FY27 guidance ahead of schedule. Profit after tax (PAT) surged 72% to ₹52 crore, driven by significant margin expansion and operational efficiencies.

Financial Performance

The revenue growth was supported by both organic and inorganic factors. Organic revenue grew 17.8% on a reported basis and 19.6% on a like-for-like basis, outpacing the underlying pharmaceutical market growth of 13.8%. Inorganic growth contributed 20.4%, primarily from the calendarization of acquisitions completed in the previous fiscal year. No new acquisitions were made during Q1FY27.

EBITDA grew 94% year-on-year, nearly 2.5 times the revenue growth rate. This disproportionate expansion was attributed to scale-led procurement economies, a higher share of revenue from the MedTech business, and the deliberate exit from low-margin accounts. The exit of low-margin businesses impacted reported growth by approximately 2.5% but released working capital for deployment in higher-return opportunities.

What the Numbers Show

A key analytical observation is the divergence between total PAT growth and PAT attributable to owners. While total PAT rose 72% to ₹52 crore, PAT attributable to owners increased by 37% to ₹38 crore. This gap is due to non-controlling interest, which stood at ₹14 crore (approximately 27% of profit before minority interest). Management clarified that this reflects the performance of majority-owned subsidiaries where residual minority stakes are held under pre-agreed call options, rather than value leakage. The minority share of profit is reinvested in the business, and the company retains full operational control.

Operational Highlights & Guidance

Return ratios showed marked improvement, with Return on Capital Employed (ROCE) doubling from 11.5% to 21.1% and Return on Equity (ROE) rising from 9% to 20.4%. Net working capital days improved to 61 days from 66 days a year ago, indicating continued structural efficiency gains.

The MedTech segment remains a critical margin lever, with revenue on track to cross ₹1,000 crore organically in FY27. This segment carries higher gross and EBITDA margins compared to the core pharmaceutical distribution business. Operationally, Entero now serves over 72,000 retail customers and 2,300 hospital customers, distributing over 83,400 SKUs across 138 warehouses in 19 states.

Management reaffirmed its FY27 guidance of approximately 23% consolidated revenue growth (excluding new acquisitions) and a 5% EBITDA margin. The company also maintained its target of converting 50% of EBITDA to operating cash flow. For the medium term, management expects organic growth to exceed 20% annually, leveraging its pan-India network and two-way moat between suppliers and customers.